How to determine whether you are at risk of infection with norovirus
By measuring IgG antibodies in oral specimens, particularly using a 3 μg/mL threshold, the method addresses the limitations of IgA-based assessments, offering a reliable method to determine norovirus infection risk and severity.
Patent Information
- Application Number
- JP2022555554
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-10-07
- Filing Date
- 2021-10-07
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-10-07
AI Technical Summary
Existing methods struggle to accurately determine the risk of norovirus infection and severity based solely on IgA antibodies in saliva, as there are cases where low IgA levels do not correlate with infection or severity, making it difficult to interpret the risk of norovirus infection.
Measuring the concentration of IgG antibodies against norovirus in oral specimens, particularly using a threshold of 3 μg/mL, to assess the risk of infection and severity, and monitoring changes in IgG antibody levels over time to provide a more reliable indication.
This approach allows for mechanical determination of norovirus infection risk and severity without relying on medical judgment, providing a more accurate assessment of infection likelihood and vaccine effectiveness.
Smart Images

Figure 0007580730000001 
Figure 0007580730000002 
Figure 0007580730000003
Abstract
Description
[Technical field]
[0001] The present invention broadly relates to a method for determining whether or not there is a risk of norovirus infection, specifically, to a method for assisting in determining whether or not a subject is susceptible to norovirus infection or whether or not a subject is susceptible to severe symptoms after infection. [Background technology]
[0002] Norovirus is an important virus that causes infectious gastroenteritis. It causes acute gastroenteritis in all age groups, from infants to the elderly. The main noroviruses that infect humans are classified into two genetic groups, Genogroup I (GI) and Genogroup II (GII), with 19 types of GI and 22 types of GII. According to the National Institute of Infectious Diseases, Infectious Disease Information Center, the majority of infectious gastroenteritis outbreaks in Japan are caused by GII.
[0003] The main symptoms of norovirus infection are diarrhea caused by an inflammatory reaction in the small intestine, vomiting and nausea caused by reduced reactivity or paralysis of the motor nerves that send stomach contents to the intestines, but the fever is mild. These symptoms last for 1-3 days and then subside. There are no drugs that are effective against norovirus infection and onset, so the only treatment available is symptomatic treatment such as fluid replacement. In addition, a norovirus vaccine to prevent infection has not yet been developed.
[0004] In epidemiological research on norovirus and research on norovirus vaccines, it is important to clarify what factors are important in preventing the onset of norovirus infection and the aggravation of the disease. In vaccine development research, indicators for determining the efficacy of vaccines are essential. [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] J Infect Dis, 2020 Jan 20, pii: jiaa021. Humoral and Mucosal Immuno Responses to Human Norovirus in the Elderly. [Non-Patent Document 2] Clin Diagn Lab Immunl. 2004 Nov,11(6):1028-1034 Diagnosis of Norwalk Virus Infection by Indirect Enzyme Immunoassay Detction of Salivary Antibodies to Recombinant Norwalk Virus Antigen Summary of the Invention [Problem to be solved by the invention]
[0006] Recently, it has been reported that IgA antibodies against norovirus in saliva are deeply involved in norovirus infection and onset / aggravation (Non-Patent Document 1). However, the reported results show that there are cases in which low levels of IgA antibodies in saliva did not result in onset / aggravation (Fig. 2), making it difficult to interpret the risk of infection based on IgA antibodies alone. In addition, the results in Fig. 1 of Non-Patent Document 2 also show that there are cases in which norovirus infection occurs despite low levels of IgA in saliva. In other words, it is difficult to interpret whether IgA antibodies are involved in norovirus infection. [Means for solving the problem]
[0007] The inventors reached the conclusion that in order to prevent norovirus infection, not only IgA antibodies (hereinafter also simply referred to as "IgA antibodies") against norovirus contained in samples from the oral cavity are involved in preventing infection, but also IgG antibodies (hereinafter also simply referred to as "IgG antibodies") against norovirus, and that IgG antibodies are considered to be a more important factor in preventing infection, which led to the completion of the present invention.
[0008] That is, the present application includes the following inventions. [1] 1. A method for assisting in determining whether a subject is susceptible to infection with norovirus or to becoming seriously ill after infection, comprising: A method comprising the step of measuring the concentration of IgG antibodies against norovirus contained in a sample derived from the oral cavity of a subject one or more times. [2] In the step of measuring the concentration, the concentration of the IgG antibody contained in the sample is measured once; The method according to [1], further comprising a step of determining that the subject is less susceptible to norovirus infection or is less likely to develop severe symptoms after infection if the concentration of IgG antibodies contained in the sample is 3 μg / mL or higher. [3] In the step of measuring the concentration, the concentration of the IgG antibody contained in the sample is measured once; The method according to [1], further comprising a step of determining that the subject is susceptible to norovirus infection or prone to severe symptoms after infection if the concentration of IgG antibodies contained in the sample is less than 3 μg / mL. [4] In the step of measuring the concentration, the concentration of the IgG antibody contained in the sample is measured at least twice; The method according to [1], further comprising a step of determining that the subject is susceptible to Norovirus infection or is likely to develop severe symptoms after infection if the concentration of IgG antibody measured at a certain point in time is less than 3 μg / mL and the concentration of IgG antibody measured thereafter increases over time, and determining that the subject is not likely to be infected with Norovirus or is not likely to develop severe symptoms after infection in other cases. [5] The method according to any of [1] to [4], wherein norovirus is classified into the Genogroup II (GII) genogroup. [6] The method according to [5], wherein the norovirus is a GII-4 strain or a GII-17 strain. [7] The method according to any of [1] to [6], further comprising a step of measuring the concentration of an IgA antibody against norovirus in addition to the concentration of an IgG antibody contained in the sample, or a step of measuring the concentration of an IgA antibody against norovirus in the sample, in the step of measuring the concentration. [8] 1. A method for evaluating the efficacy of administration of a norovirus vaccine, comprising: A method comprising a step of measuring the concentration of IgG antibodies against norovirus contained in a sample derived from the oral cavity of a subject. [9] The method described in [8], further comprising a step of determining that the norovirus vaccine is effective if the concentration of IgG antibodies contained in the sample, which was less than 3 μg / mL before administration, increases to 3 μg / mL or more after administration of the norovirus vaccine.
[10] In the step of measuring the concentration, the concentration of IgG antibody contained in a sample derived from a subject administered with a norovirus vaccine is measured at least twice; The method according to [8] or [9], comprising a step of determining that the norovirus vaccine is effective if the concentration of IgG antibody contained in a sample derived from the subject before administration of the norovirus vaccine is less than 3 μg / mL and if the concentration of IgG antibody measured after administration increases to 3 μg / mL or more.
[11] The method according to any of [8] to
[10] , wherein norovirus is classified into the Genogroup II (GII) genogroup.
[12] The method according to
[11] , wherein the norovirus is a GII-4 strain or a GII-17 strain.
[13] The method according to any of [8] to
[12] , further comprising a step of measuring the concentration of an IgA antibody against norovirus in addition to the concentration of an IgG antibody contained in the sample, or a step of measuring the concentration of an IgA antibody against norovirus in the sample, in the step of measuring the concentration.
[14] 1. A method for assisting in the decision of whether to administer a Norovirus vaccine, comprising: A method comprising a step of measuring the concentration of IgG antibodies against norovirus contained in a sample derived from the oral cavity of a subject.
[15] The method according to
[14] , comprising a step of determining that the norovirus vaccine should be administered if the concentration of IgG antibodies in the sample before administration of the norovirus vaccine is less than 3 μg / mL.
[16] In the step of measuring the concentration, the concentration of the IgG antibody contained in the sample is measured at least twice; The method according to
[14] or
[15] , further comprising a step of determining that an additional dose of norovirus vaccine should be administered if the concentration of IgG antibodies in the sample after administration of the norovirus vaccine falls to less than 3 μg / mL.
[17] The method according to any of
[14] to
[16] , wherein norovirus is classified into the Genogroup II (GII) genogroup.
[18] The method according to
[17] , wherein the norovirus is a GII-4 strain or a GII-17 strain.
[19] The method according to any of
[14] to
[18] , further comprising a step of measuring the concentration of an IgA antibody against norovirus in addition to the concentration of an IgG antibody contained in the sample, or a step of measuring the concentration of an IgA antibody against norovirus in the sample, in the step of measuring the concentration. Effect of the Invention
[0009] According to the present invention, by using the concentration of IgG antibody as an indicator, it becomes possible to mechanically determine the presence or absence of a risk of norovirus infection without relying on the judgment of a doctor. [Brief description of the drawings]
[0010] [Figure 1a] FIG. 1a shows the results for the group with elevated levels of IgA antibodies against the GII-4 strain. [Figure 1b] FIG. 1b shows the results for the group in which the concentration of IgA antibodies against the GII-4 strain was reduced. [Figure 1c] FIG. 1c shows the results for the group in which the concentration of IgA antibodies against the GII-4 strain did not change. [Figure 2a] FIG. 2a shows the results for the group with increased levels of IgG antibodies against the GII-4 strain. [Figure 2b] FIG. 2b shows the results for the group in which the concentration of IgG antibody against the GII-4 strain was decreased. [Figure 2c] FIG. 2c shows the results for the group in which the concentration of IgG antibody against the GII-4 strain did not change. [Figure 3a] FIG. 3a shows the results for the group with increased levels of IgA antibodies against the GII-17 strain. [Figure 3b] FIG. 3b shows the results for the group in which the concentration of IgA antibodies against the GII-17 strain was reduced. [Figure 3c] FIG. 3c shows the results for the group in which the concentration of IgA antibodies against the GII-17 strain did not change. [Figure 4a] FIG. 4a shows the results for the group with increased levels of IgG antibodies against the GII-17 strain. [Figure 4b] FIG. 4b shows the results for the group in which the concentration of IgG antibody against the GII-17 strain was decreased. [Figure 4c] FIG. 4c shows the results for the group in which the concentration of IgG antibody against the GII-17 strain did not change. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] Hereinafter, an embodiment of the present invention (hereinafter, referred to as "the present embodiment") will be described, but the scope of the present invention should not be interpreted as being limited to the following embodiment.
[0012] (Decision support method) In a first aspect, there is provided a method for assisting in determining whether a subject is susceptible to Norovirus infection or to the development of severe symptoms after infection, the method comprising a step of measuring one or more times the concentration of IgG antibodies against Norovirus contained in a sample derived from the subject's oral cavity.
[0013] The subject may be any mammal suspected of being infected with Norovirus, with preferred subjects contemplated by the present methods being humans.
[0014] From the viewpoint of local immunity, the specimen is a specimen from the oral cavity of the subject, such as saliva, sputum, throat swabs, mucosal tissue, etc. From the viewpoint of reducing the burden on the subject during collection, it is preferable to use saliva as the specimen. Saliva has a clear relationship with antibodies, and from that viewpoint, it can be said to be a preferable specimen. The specimen can be collected by a method known to those skilled in the art. For example, in the case of saliva, the subject can directly collect a collection tube containing a predetermined amount of saliva, for example, 1 mL or more.
[0015] The collected sample may be subjected to additional steps before the amount of antibody is measured, for example, the collected saliva may be centrifuged and the resulting supernatant diluted before the amount of antibody is measured.
[0016] The collected sample is subjected to a step of measuring the antibody concentration one or more times. The immunoglobulin to be measured may be of the IgG class, and may be any of the subclasses IgG1, IgG2, IgG3, and IgG4, or a combination thereof.
[0017] Using the concentration of IgG antibody contained in a specimen as an index, the risk associated with norovirus infection, specifically, the risk of being infected with norovirus and the risk of becoming severe due to the onset of infection, is evaluated. The concentration of IgG antibody contained in a specimen is measured once, and when the concentration of IgG antibody contained in the specimen is a predetermined concentration or more, for example, 2.7 to 3.3 μg / mL or more, preferably 3 μg / mL or more, more preferably 3.3 μg / mL or more, it can be determined that the subject is unlikely to be infected with norovirus or is unlikely to become severe after infection. On the other hand, when the concentration of IgG antibody contained in a specimen is measured once, and when the concentration of IgG antibody contained in the specimen is less than a predetermined concentration, for example, less than 2.7 to 3.3 μg / mL, preferably less than 3 μg / mL, more preferably less than 2.7 μg / mL, it can be determined that the subject is likely to be infected with norovirus or is likely to become severe after infection.
[0018] Since the concentration of IgG antibodies may change over time, particularly before and after infection, it is preferable to perform the measurement step multiple times. For example, in one embodiment, in the IgG antibody measurement step, the concentration of IgG antibodies contained in a sample is measured at least twice. In this case, if the concentration of IgG antibodies measured at a certain point in time is less than a predetermined concentration, for example, less than 2.7 to 3.3 μg / mL, preferably less than 3 μg / mL, more preferably less than 2.7 μg / mL, and the concentration of IgG antibodies measured thereafter increases over time, it can be determined that the subject is susceptible to infection with norovirus or is likely to become severe after infection. In other cases, that is, if the concentration is equal to or greater than a predetermined concentration, for example, equal to or greater than 2.7 to 3.3 μg / mL, preferably equal to or greater than 3 μg / mL, more preferably equal to or greater than 3.3 μg / mL, it can be determined that the subject is unlikely to be infected with norovirus or is unlikely to become severe after infection.
[0019] The concentration of IgG antibodies can be measured by known techniques, such as immunological techniques, including enzyme-linked immunosorbent assay (ELISA), immunostaining (including fluorescent antibody technique, enzyme antibody technique, heavy metal-labeled antibody technique, and radioisotope-labeled antibody technique), a combination of electrophoretic separation and detection using fluorescence, enzymes, radioisotopes, etc. (including Western blotting and fluorescent two-dimensional electrophoresis), dot blotting, latex agglutination (LA) and immunochromatography.
[0020] As used herein, "norovirus" refers to noroviruses of any genotype. Examples of norovirus genotypes include genogroup I and II. Although not intended to be limiting, GI types include GI-4 strains, and GII types include GII-4 and GII-17 strains.
[0021] In the measurement step, in addition to IgG, the concentration of a component contained in the sample that is known to be related to norovirus infection, for example, an IgA antibody against norovirus, may be measured. The concentration of IgA antibody alone is not an indicator for determining whether a person is susceptible to norovirus infection or whether the infection is likely to become severe after infection, but it can be used as an auxiliary when evaluating the concentration of IgG antibody. In a preferred embodiment, the concentration of IgA antibody contained in the sample is measured in the same process as that of IgG antibody, but a separate process of measuring the concentration of IgA antibody may be added. IgA antibody is involved in suppressing the onset of norovirus infection and preventing the disease from becoming severe, and when the concentration of IgA antibody in the sample increases from the concentration measured previously, preferably by four times or more, the subject from whom the sample was collected is suspected of being infected with norovirus.
[0022] The risk associated with norovirus infection can be determined by using the concentration of IgG antibodies contained in the sample as a supplementary measure, and further by a doctor's comprehensive diagnosis based on the clinical symptoms of the subject and the infection status in the surrounding area. This method may be combined with a known method used for diagnosing norovirus. One such known method is a method for detecting norovirus in feces using a test kit.
[0023] Virological diagnostic methods are a reliable method for testing whether or not someone is infected with norovirus. For example, since a large amount of the virus is excreted in the feces and vomit of a patient (subject) infected with norovirus, the presence or absence of norovirus in such specimens can be confirmed by electron microscopy, reverse transcription PCR, real-time PCR, etc.
[0024] (Methods for evaluating vaccine effectiveness) In a second aspect, a method for evaluating the effectiveness of administration of a Norovirus vaccine is provided, the method comprising a step of measuring the concentration of IgG antibodies against Norovirus contained in a sample derived from the oral cavity of a subject.
[0025] The subject may be any mammalian animal that has been administered a norovirus vaccine, and the preferred subject envisaged in this method is a human. The norovirus vaccine is not particularly limited as long as it recognizes a norovirus antigen. The subject is as described above.
[0026] In this method, the effectiveness of administration of a norovirus vaccine can be evaluated using IgG antibodies as an index, similarly to the decision-assisting method. In a preferred embodiment, the norovirus vaccine can be determined to be effective when the concentration of IgG antibodies contained in a sample increases to a predetermined concentration or higher, for example, 2.7 to 3.3 μg / mL or higher, preferably 3 μg / mL or higher, more preferably 3.3 μg / mL or higher, after administration of the norovirus vaccine. For example, the norovirus vaccine is determined to be effective when the concentration of IgG antibodies contained in a sample, which was less than 3 μg / mL before administration, increases to 3 μg / mL or higher after administration of the norovirus vaccine.
[0027] Since the concentration of IgG antibodies may change over time, particularly before and after administration of a norovirus vaccine, it is preferable to perform the measurement step multiple times. For example, in one embodiment, the concentration of IgG antibodies contained in a specimen is measured at least twice in the IgG antibody measurement step. In this case, if the concentration of IgG antibodies contained in a specimen derived from a subject before administration of a norovirus vaccine is less than a predetermined concentration, for example, less than 2.7 to 3.3 μg / mL, preferably less than 3 μg / mL, more preferably less than 2.7 μg / mL, and the concentration of IgG antibodies measured after administration is increased to a predetermined concentration or more, for example, 2.7 to 3.3 μg / mL or more, preferably 3 μg / mL or more, more preferably 3.3 μg / mL or more, it can be determined that the administered norovirus vaccine is effective.
[0028] In the measurement step, in addition to IgG, the concentration of a component contained in the sample that is known to be related to the evaluation of the effectiveness of a norovirus vaccine, for example, an IgA antibody against norovirus, may be measured. The concentration of IgA antibody alone is not an indicator for determining whether or not a person is susceptible to norovirus infection or whether or not the person is likely to become seriously ill after infection, but it can be used as an auxiliary when evaluating the concentration of IgG antibody. In a preferred embodiment, the concentration of IgA antibody contained in the sample is measured in the same step as that of IgG antibody, but a step of measuring the concentration of IgA antibody separately may be added.
[0029] The norovirus vaccine may be directed against any genotype of norovirus, but is preferably directed against GI type norovirus or / and GII type norovirus.
[0030] (Method of determining administration timing) In a third aspect, there is provided a method for assisting in the decision of whether to administer a Norovirus vaccine, comprising: The method includes a step of measuring the concentration of IgG antibody against norovirus contained in a sample derived from the oral cavity of a subject.
[0031] The subject may be any mammal suspected of being infected with Norovirus, with the preferred subject contemplated by the present method being a human. The subject is as described above.
[0032] Like the decision-assisting method, this method can determine whether or not a norovirus vaccine should be administered using IgG antibody as an index. In a preferred embodiment, it can be determined that a norovirus vaccine should be administered when the concentration of IgG antibody contained in a specimen derived from a subject before administration of the norovirus vaccine is less than a predetermined concentration, for example, less than 2.7 to 3.3 μg / mL, preferably less than 3 μg / mL, more preferably less than 2.7 μg / mL.
[0033] Since the concentration of IgG antibodies may change over time, particularly before and after infection, it is preferable to perform the measurement step multiple times. In particular, the increased concentration of IgG antibodies also decreases over time. In addition, since noroviruses, which are RNA viruses like seasonal influenza viruses, often mutate and the epidemic strains change in 1 or 2 years, it is preferable to measure the concentration of IgG antibodies before and after vaccine administration, and determine that an additional norovirus vaccine should be administered if the concentration of IgG antibodies contained in the sample after administration has decreased to less than 3 μg / mL. Therefore, for example, in one embodiment, in the IgG antibody measurement step, the concentration of IgG antibodies contained in the sample is measured at least twice. Furthermore, in the measurement step, the concentration of IgA antibodies against norovirus may be measured.
[0034] The present invention will be specifically described below by showing examples, but the present invention is not limited to these examples. EXAMPLES
[0035] Subject The subjects were 106 outpatients at Niigata University Hospital, excluding those taking steroids and those with cancer. Patients taking steroids were excluded because it was thought that steroids may affect the body's immune system, and that this could prevent antibodies from increasing even if they were infected. Cancer patients were also excluded because they were likely to have been taking drugs that affect the immune system. The gender breakdown was as follows: Men: 60 Women: 46 (median age: 66.5 years old)
[0036] Saliva sample sampling Saliva samples were collected from the subjects at the following times: Pre-sample: Saliva sampling from October to November 2018 Post sample: Saliva sampling between March and May 2019
[0037] Sampling was performed by the subject directly putting 1mL or more of saliva into a collection tube. After centrifugation (10,000 rpm, 5 minutes) of 180μL of collected saliva in a centrifuge tube, 225μL of PBS (phosphate buffer solution) was added to 75μL of the supernatant (4-fold dilution), and a 4-fold dilution series was prepared up to 256-fold dilution, and the antibody amount was measured using each diluted sample. In terms of non-specific reactions and sensitivity, the antibody amount in the 64-fold diluted sample was finally used.
[0038] Measurement of salivary IgA and IgG antibody concentrations against norovirus The concentrations of IgA and IgG antibodies in the collected saliva were measured by ELISA according to the following protocol.
[0039] ELISA Protocol GII-4 aomori strain (virus like particle: VLP (GII-4)) and GII-17 kawasaki strain VLP (GII-17) expressed in tobacco plants using the magnICON (registered trademark) system were diluted to a concentration of 1 μg / mL with PBS, pH 7.4 (Nacalai). Add 50μL of each diluted VLP to each well of a 96-well microplate (Nunc) and leave at 4℃ overnight. After standing, the plate is washed three times with PBS, pH 7.4 (PBST) containing 0.1% Polyoxyethylene(20) Sorbitan Monolaurate (WAKO). After washing, add 80uL of PBSB (pH 7.4) containing 1% Bovine Serum Albumin (Sigma) to each well for blocking, and incubate at room temperature for 2 hours. Discard the PBSB. Add 50μL of saliva sample diluted 64-fold with PBS to each well and incubate at room temperature for 4 hours. Wash the plate 3 times with PBST. Add 50 μL of peroxidase-labeled anti-human IgG antibody (goat) (SouthernBiotech) and peroxidase-labeled anti-human IgA antibody (goat) (SouthernBiotech) diluted 2,000-fold with PBSTB to each well and incubate at room temperature for 2 hours. Afterwards, wash the plate 5 times with PBST. After washing, add 50μL of TMB ELISA substrate solution (Thermo Scientific) to each well. Incubate at room temperature in the dark until color development is observed. Add 50 μL of STOP solution (Invitrogen) to each well to stop the reaction. Measure the absorbance at 450nm. A calibration curve was created using humanized IgA and humanized IgG antibodies against GII-4 and GII-17, respectively, developed by Dr. Takahashi of the Department of Immunology at the National Institute of Infectious Diseases. The antibody concentrations were calculated from the absorbance of the samples.
[0040] The results of the ELISA are shown in Figures 1 to 4.
[0041] Changes in salivary IgA and IgG antibody concentrations against GII-4 strain Comparing the IgA and IgG antibody concentrations in the Pre sample with those in the Post sample, we were able to divide the IgA and IgG antibody samples into three groups: one in which the antibody concentration in the Pre sample increased in the Post sample, one in which it decreased, and one in which it remained almost unchanged (Figure 1).
[0042] Figure 1 shows the results of comparing the salivary IgA antibody concentrations against the GII-4 strain in pre- and post-samples. a) is a distribution diagram of IgA antibody concentrations in pre- and post-samples from each volunteer in the group in which the IgA antibody concentration increased, b) was decreased, and c) was unchanged.
[0043] Generally, when infected with a virus, the concentration of antibodies against the infectious virus increases. The group with an increased IgA antibody concentration (Figure 1a) is suspected to have had some kind of infection with the GII-4 strain during the pre- and post-sampling periods. The group with a decreased concentration (Figure 1b) is thought to have had no infection during the sampling period.
[0044] When comparing the IgA antibody concentration distribution of pre-immune mice in the group with an increased IgA antibody concentration with that of pre-immune mice in the group with a decreased IgA antibody concentration, the IgA antibody concentration distribution of the decreased group was higher. In other words, it is thought that when the IgA antibody concentration is low, it is easier to become infected with the GII-4 strain, but when it is high, it is less likely to become infected.
[0045] Volunteer No. 48 developed symptoms such as vomiting (his wife also developed symptoms later), and norovirus infection was strongly suspected. However, the IgA antibody concentration in No. 48's pre-existing blood was high at 10 μg / mL, which is equivalent to the IgA antibody concentration distribution in the pre-existing blood of the group that had decreased, but infection is strongly suspected. Prevention of infection cannot be explained solely by IgA antibodies in saliva.
[0046] Figure 2 shows the results of comparing salivary IgG antibody concentrations against the GII-4 strain in pre- and post-samples. a) is a distribution diagram of IgG antibody concentrations in pre- and post-samples from each volunteer in the group in which the IgG antibody concentration increased, b) was decreased, and c) was unchanged.
[0047] As in Figure 1, the group in which the IgG antibody concentration increased (Figure 2a)) is suspected to have had some kind of infection with the GII-4 strain during the pre- and post-sampling periods. In addition, the group in which the concentration decreased (Figure 2b)) is thought to have had no infection during the sampling period, and therefore had been infected before sampling.
[0048] As with the IgA antibody concentration in Figure 1, when comparing the distribution of IgG antibody concentrations in Pre in the group with an increased IgG antibody concentration and the group with a decreased IgG antibody concentration, the IgG antibody concentration distribution in the decreased group is higher. Unlike the IgA antibody concentration, in the case of IgG antibody concentration, the IgG antibody concentration in Pre was distributed at less than 3 μg / mL in the increased group, and the IgG antibody concentration in Pre was distributed at 3 μg / mL or more in the decreased group. In other words, it is thought that when the IgG antibody concentration is less than 3 μg / mL, infection with the GII-4 strain occurs, but when it is 3 μg / mL or more, infection does not occur. However, no correlation was confirmed between the fluctuations in IgG antibody concentration and the fluctuations in IgA antibody concentration.
[0049] The IgA antibody concentration in the pre of volunteer No. 48, who was strongly suspected of infection, was high at 10 μg / mL, and was equivalent to the IgA antibody concentration distribution in the pre of the decreased group, but the IgG antibody concentration in the pre of No. 48 was clearly lower than the IgG antibody concentration distribution in the decreased group. From these results, it was thought that not only IgA antibodies in saliva but also IgG antibodies are involved in preventing infection, and that IgG antibodies are rather a more important factor in preventing infection.
[0050] Changes in salivary IgA and IgG antibody concentrations against GII-17 strain Similar to the results for the GII-4 strain, when the IgA and IgG antibody concentrations in the Pre sample were compared with those in the Post sample, the subjects were divided into three groups: one in which the antibody concentration in the Pre sample increased compared to the Post sample, one in which the antibody concentration in the Post sample decreased, and one in which the antibody concentration in the Post sample remained almost unchanged (Figure 3).
[0051] Figure 3 shows the results of comparing the salivary IgA antibody concentrations against the GII-17 strain in pre- and post-samples. a) is a distribution diagram of IgA antibody concentrations in pre- and post-samples from each volunteer in the group in which the IgA antibody concentration increased, b) was decreased, and c) was unchanged.
[0052] When comparing the IgA antibody concentration distribution of pre-immune mice in the group with an increased IgA antibody concentration with that of pre-immune mice in the group with a decreased IgA antibody concentration, the IgA antibody concentration distribution of the group with a decreased IgA antibody concentration is higher, but the IgA antibody concentration distributions of both groups overlap in part. It is thought that when the IgA antibody concentration is low, it is easier to become infected with the GII-17 strain, and when it is high, it is less likely to become infected.
[0053] Figure 4 shows the results of comparing salivary IgG antibody concentrations against the GII-17 strain in pre- and post-samples. a) is a distribution diagram of IgG antibody concentrations in pre- and post-samples from each volunteer in the group in which IgG antibody concentrations increased, b) was decreased, and c) was unchanged.
[0054] As in Figure 3, the group in which the IgG antibody concentration increased (Figure 4a)) is suspected to have been infected with the GII-17 strain during the pre- and post-sampling periods. The group in which the concentration decreased (Figure 4b)) is considered to have had no infection during the sampling period.
[0055] As mentioned above, when comparing the IgG antibody concentration distribution of Pre in the group with an increased IgG antibody concentration with that of the group with a decreased IgG antibody concentration, the IgG antibody concentration distribution of the decreased group is higher. Unlike the IgA antibody concentration, in the case of IgG antibody concentration, as in Figure 2, the IgG antibody concentration of Pre was distributed at less than 3 μg / mL in the increased group, and the IgG antibody concentration of Pre was distributed at 3 μg / mL or more in the decreased group. In other words, it is thought that when the IgG antibody concentration is less than 3 μg / mL, it is easy to be infected with the GII-17 strain, but when it is 3 μg / mL or more, it is difficult to be infected.
[0056] The IgA antibody concentration in the pre of volunteer No. 48, who was strongly suspected of infection (and No. 108, who was suspected of infection but asymptomatic), was equivalent to the IgA antibody concentration distribution in the pre of the decreased group, but the IgG antibody concentration in the pre of No. 48 was clearly lower than the IgG antibody concentration distribution in the decreased group. It is thought that not only IgA antibodies in saliva but also IgG antibodies are involved in preventing infection, and that IgG antibodies are rather a more important factor in preventing infection.
Claims
1. 1. A method for assisting in determining whether a subject is susceptible to infection with norovirus or to becoming seriously ill after infection, comprising: 1) measuring the concentration of IgG antibodies against norovirus contained in a sample from the oral cavity of a subject one or more times; 2) assisting in determining that the subject is unlikely to be infected with norovirus or unlikely to become seriously ill after infection when the concentration of IgG antibodies contained in the sample is 3 μg / mL or more, and that the subject is likely to be infected with norovirus or likely to become seriously ill after infection when the concentration of IgG antibodies contained in the sample is less than 3 μg / mL; A method comprising:
2. In step 1), the concentration of IgG antibody contained in the sample is measured at least twice; The method of claim 1, further comprising a step of assisting in determining that a subject is susceptible to Norovirus infection or is prone to severe disease after infection if the concentration of IgG antibody measured at a certain point in time is less than 3 μg / mL and the concentration of IgG antibody measured thereafter increases over time, and otherwise assisting in determining that a subject is not likely to be infected with Norovirus or is not likely to become severely ill after infection.
3. The method according to claim 1 or 2, wherein the norovirus is classified into Genogroup II (GII) genogroup.
4. The method according to claim 3, wherein the norovirus is a GII-4 or GII-17 strain.
5. A method according to any one of claims 1 to 4, further comprising, in step 1), measuring the concentration of IgA antibodies against norovirus together with the concentration of IgG antibodies contained in the sample, or measuring the concentration of IgA antibodies against norovirus contained in the sample.
6. 1. A method for assisting in determining the efficacy of administration of a Norovirus vaccine, comprising: 1) measuring the concentration of IgG antibodies against norovirus contained in a sample obtained from the oral cavity of a subject; 2) the norovirus vaccine is effective if the concentration of IgG antibodies in the sample, which was less than 3 μg / mL before administration, increases to 3 μg / mL or more after administration of the norovirus vaccine; , and A method comprising:
7. In step 1), the concentration of IgG antibodies contained in a sample derived from a subject administered a norovirus vaccine is measured at least twice; The method of claim 6, further comprising a step of assisting in determining that the Norovirus vaccine is effective if the concentration of IgG antibodies contained in a saliva sample from the subject before administration of the Norovirus vaccine is less than 3 μg / mL and the concentration of IgG antibodies measured after administration increases to 3 μg / mL or more.
8. The method according to claim 6 or 7, wherein the Norovirus is classified into Genogroup II (GII) genogroup.
9. The method according to claim 8, wherein the norovirus is a GII-4 or GII-17 strain.
10. A method according to any one of claims 6 to 9, further comprising, in step 1), measuring the concentration of IgA antibodies against norovirus together with the concentration of IgG antibodies contained in the sample, or measuring the concentration of IgA antibodies against norovirus contained in the sample.
11. 1. A method for assisting in the decision of whether to administer a Norovirus vaccine, comprising: 1) measuring the concentration of IgG antibodies against norovirus contained in a sample obtained from the oral cavity of a subject; 2) assisting in the decision to administer the norovirus vaccine when the concentration of IgG antibodies in the sample before administration of the norovirus vaccine is less than 3 μg / mL; A method comprising:
12. In step 1), the concentration of IgG antibody contained in the sample is measured at least twice; The method of claim 11, further comprising a step of assisting in determining that an additional dose of Norovirus vaccine should be administered if the concentration of IgG antibodies in a sample after administration of the Norovirus vaccine falls to less than 3 μg / mL.
13. The method according to claim 11 or 12, wherein the Norovirus is classified into Genogroup II (GII) genogroup.
14. The method according to claim 13, wherein the norovirus is a GII-4 or GII-17 strain.
15. A method according to any one of claims 11 to 14, further comprising, in step 1), measuring the concentration of IgA antibodies against norovirus in addition to the concentration of IgG antibodies contained in the sample, or measuring the concentration of IgA antibodies against norovirus in the sample.
